Adverse Effects

Citations 91-96 of 96 total displayed.

Past content (since May 1999):

Original Contributions
Early Morning Off-Medication Dyskinesias, Dystonia, and Choreic Subtypes

Esther Cubo; Jean-Michel Gracies; Reina Benabou; Charles Warren Olanow; Rema Raman; Sue Leurgans; Christopher G. Goetz
Arch Neurol 2001; 58: 1379-1382. [Abstract] [Full text] [PDF]  

Original Contributions
Induction by Dopamine D₁ Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease

O. Rascol; J. G. Nutt; O. Blin; C. G. Goetz; J. M. Trugman; C. Soubrouillard; J. H. Carter; L. J. Currie; N. Fabre; C. Thalamas; W. J. Giardina; S. Wright
Arch Neurol 2001; 58: 249-254. [Abstract] [Full text] [PDF]  

Original Contributions
Altered Mental Status in Patients With Cancer

Rogerio Tuma; Lisa M. DeAngelis
Arch Neurol 2000; 57: 1727-1731. [Abstract] [Full text] [PDF]  

Original Contributions
Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses

G. Anthony Broe; David A. Grayson; Helen M. Creasey; Louise M. Waite; Barney J. Casey; Hayley P. Bennett; William S. Brooks; Glenda M. Halliday
Arch Neurol 2000; 57: 1586-1591. [Abstract] [Full text] [PDF]  

Neurotherapeutics
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial

Stanley Fahn
Arch Neurol 1999; 56: 529-535. [Extract] [Full text] [PDF]  

Original Contributions
Prospective Study of New-Onset Seizures in Patients With Human Immunodeficiency Virus Infection: Etiologic and Clinical Aspects

Berta Pascual-Sedano; Alejandro Iranzo; Joan Martí-Fàbregas; Pere Domingo; Antonio Escartin; Montserrat Fuster; Josep L. Barrio; Maria A. Sambeat
Arch Neurol 1999; 56: 609-612. [Abstract] [Full text] [PDF]  

[First page]   [Previous page]   Pages: 1 2 3 4 5 6 7 8 9 10